Crossmark

The efficacy, safety, and persistence of vedolizumab versus adalimumab in patients with inflammatory bowel disease: a systematic review and meta-analysis

Crossref DOI link: https://doi.org/10.1007/s10787-025-01710-4

Published Online: 2025-03-15

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chen, Zhixin

Li, Huo

Li, Zhongzhuan

Ouyang, Rong

Huang, Shijiang

Qin, Shufen

Qin, Jing

Huang, Jiean https://orcid.org/0009-0005-2381-6998
License Information

Text and Data Mining valid from 2025-03-15

Version of Record valid from 2025-03-15
More Information

Article History

Received: 23 November 2024

Accepted: 22 February 2025

First Online: 15 March 2025

Declarations

:

: All authors have confirmed no conflicts of interest related to this study, ensuring transparency and research integrity.

: As our study was a meta-analysis that did not involve direct patient interaction or access to personal data, no ethical approval was required.

Document is current

Any future updates will be listed below